Opportunity Information: Apply for CDC RFA GH21 2157
This grant opportunity, titled "Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR," is a CDC-funded cooperative agreement focused on improving Namibia's national laboratory system to support long-term control of HIV and tuberculosis. It sits within the broader PEPFAR context, meaning the practical aim is to strengthen diagnostic services so that patients are tested efficiently, results are reliable and timely, and programs can more accurately measure outcomes like viral load suppression and early infant diagnosis coverage. The CDC frames the work as a five-year effort centered on diagnostic network optimization, which is essentially a structured way to map and improve how samples, data, instruments, and patients move through the laboratory and clinical ecosystem.
In terms of funding mechanics, the notice lists an award ceiling for Year 1 as "0 (none)," which typically signals that no strict upper cap is being set in the public synopsis even though funding is anticipated. At the same time, CDC indicates an approximate total funding level of $3.5 million for the first year, dependent on the availability of funds. The opportunity number is CDC-RFA-GH21-2157, the instrument is a cooperative agreement (which generally implies substantial involvement by CDC in technical direction and collaboration), and it is categorized under health (CFDA 93.067). The notice anticipated one award, suggesting the CDC likely intended to support a single implementing partner or lead organization to coordinate work with the Namibia Institute of Pathology and national stakeholders.
The core technical approach is diagnostic network optimization (DNO) across Namibia's laboratory system. DNO is emphasized as the main overarching activity because it helps identify where the system is falling short and then targets fixes that matter for epidemic control, such as reducing turnaround times for viral load testing, ensuring adequate coverage for infant diagnosis, and strengthening the ability to detect and respond to outbreaks. The language also makes clear that the system improvements are not just for routine HIV and TB services but should also help the country respond to outbreak needs as they arise, which implies building more resilient transport, testing capacity, and data visibility.
The notice lays out four major activity areas. First is establishing a national specimen transport system built on the Namibia Institute of Pathology (NIP) platform. This is about making sure specimens (for example, blood samples for viral load or infant diagnosis, and sputum or other samples relevant to TB testing) can consistently travel from clinics and peripheral sites to the right laboratories and then have results returned to clinicians quickly. A national transport backbone usually involves route design, scheduling, courier systems, temperature and biosafety considerations, tracking mechanisms, and performance monitoring so that delays and lost samples are minimized.
Second are workflow analyses to assess testing needs based on the number of patients on antiretroviral therapy. This connects laboratory demand forecasting directly to treatment program realities: as more people start and remain on ART, viral load testing volumes rise, and labs must plan staffing, reagent supply, instrument placement, and sample referral patterns accordingly. Workflow analysis typically includes mapping processes from sample collection through accessioning, testing, result validation, and reporting, then identifying bottlenecks such as manual data entry, batching delays, or uneven distribution of workload across facilities.
Third is assessing instrument utilization. This focus is meant to ensure that existing diagnostic equipment is being used effectively and that capacity matches demand geographically and technically. In practice, utilization assessment can reveal problems like machines sitting idle due to lack of reagents, maintenance gaps, insufficient training, power instability, or poor sample referral patterns. It can also identify sites that are overloaded and need redistribution of testing, additional platforms, or changes in specimen routing. Optimizing utilization is a major cost and quality lever because it can improve turnaround time and test coverage without immediately requiring new capital purchases.
Fourth is establishing a national unique patient identifier. This is a major data systems improvement that aims to connect patient records across time and locations, which is particularly important in HIV care because patients may move between facilities and need repeated viral load testing over years. A unique identifier helps ensure that a viral load result is attributed to the correct person, reduces duplicate records, and makes longitudinal tracking possible. The notice explicitly links this to tracking patients from one viral load test to the next so suppression rates are accurate for all patients on ART. In other words, the goal is not just better lab operations, but better measurement and accountability for program outcomes.
The intended public health results are spelled out in practical terms. By improving transport, workflows, instrument use, and patient identification, Namibia should be able to more accurately measure and improve viral load suppression among people on ART, which is one of the main indicators of effective HIV treatment and reduced onward transmission. The grant also aims to expand and strengthen early infant diagnosis, pushing coverage beyond the stated current level of 80, which implies the program wants to find HIV-exposed infants earlier and link them to care promptly. Finally, the opportunity highlights HIV/TB co-infection explicitly, with the aim of ensuring that HIV patients who are also infected with TB are properly diagnosed and treated, reflecting the high clinical and public health importance of integrated HIV and TB diagnostic services.
Administratively, the opportunity was created on March 3, 2021, with an original closing date of May 2, 2021, and applications were required to be submitted electronically by 11:59 p.m. Eastern Time on the due date. Eligibility is listed broadly as "Others (see text field entitled Additional Information on Eligibility for clarification)," which indicates that the full funding announcement likely defined specific eligible entity types or conditions not included in the excerpt. Overall, the opportunity is best understood as a systems-strengthening award designed to use NIP as the operational backbone for national laboratory improvements, with the end goal of sustaining epidemic control of HIV and TB through more accessible, higher-quality, and better-integrated diagnostic services.Apply for CDC RFA GH21 2157
- The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
- This funding opportunity was created on Mar 03, 2021.
- Applicants must submit their applications by May 02, 2021 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR."
Who is funding this opportunity?
This is a CDC-funded cooperative agreement offered within the broader PEPFAR context.
What is the main goal of the award?
The main goal is to strengthen Namibia's national laboratory system to support sustained, long-term control of HIV and tuberculosis by improving diagnostic services so testing is efficient, results are reliable and timely, and program outcomes can be measured more accurately.
What is the funding mechanism (award type)?
The instrument is a cooperative agreement, which generally means CDC is expected to have substantial involvement in technical direction and collaboration during implementation.
What is the opportunity number?
The opportunity number is CDC-RFA-GH21-2157.
What CFDA number and category are associated with this funding?
The opportunity is categorized under health and is listed under CFDA 93.067.
How long is the project period?
The notice frames the work as a five-year effort focused on strengthening the laboratory system through diagnostic network optimization.
How many awards did CDC anticipate making?
The notice anticipated one award, suggesting a single implementing partner or lead organization would coordinate work with the Namibia Institute of Pathology and national stakeholders.
How much funding is expected?
CDC indicated an approximate total funding level of $3.5 million for the first year, dependent on the availability of funds.
Why does the notice show an award ceiling of "0 (none)" for Year 1?
The notice lists an award ceiling for Year 1 as "0 (none)," which typically signals that no strict upper cap is being set in the public synopsis even though funding is anticipated.
What is the central technical approach described in the opportunity?
The core approach is diagnostic network optimization (DNO), described as a structured way to map and improve how samples, data, instruments, and patients move through the laboratory and clinical ecosystem across Namibia.
What kinds of problems is diagnostic network optimization meant to address?
DNO is emphasized as the overarching activity because it helps identify where the laboratory system is falling short and then target improvements that matter for epidemic control, such as reducing turnaround times for viral load testing, ensuring adequate early infant diagnosis coverage, and strengthening the ability to detect and respond to outbreaks.
Does the opportunity focus only on routine HIV and TB services?
No. The notice indicates system improvements should support routine HIV and TB services and also strengthen the country's ability to respond to outbreak needs as they arise.
What are the major activity areas included in the notice?
The notice lays out four major activity areas: (1) establishing a national specimen transport system built on the Namibia Institute of Pathology (NIP) platform, (2) conducting workflow analyses to assess testing needs based on the number of patients on antiretroviral therapy, (3) assessing instrument utilization, and (4) establishing a national unique patient identifier.
What is meant by a national specimen transport system, and who is it built on?
This refers to establishing a national specimen transport system built on the Namibia Institute of Pathology (NIP) platform, intended to ensure specimens can consistently travel from clinics and peripheral sites to the right laboratories and results can be returned to clinicians quickly.
What specimen types are mentioned as examples?
The notice gives examples such as blood samples for viral load and early infant diagnosis, and sputum or other samples relevant to TB testing.
What does the notice imply a national transport backbone may involve?
It implies activities such as route design, scheduling, courier systems, temperature and biosafety considerations, tracking mechanisms, and performance monitoring to minimize delays and lost samples.
What are the workflow analyses supposed to assess?
The workflow analyses are intended to assess testing needs based on the number of patients on antiretroviral therapy (ART), linking laboratory demand forecasting to treatment program realities as viral load testing volumes rise with ART scale-up.
What kinds of bottlenecks might workflow analysis identify (as described in the notice)?
The notice describes that workflow analysis typically maps processes from sample collection through accessioning, testing, result validation, and reporting, and can identify bottlenecks such as manual data entry, batching delays, or uneven distribution of workload across facilities.
What does "instrument utilization assessment" mean in this context?
It refers to assessing whether existing diagnostic equipment is being used effectively and whether capacity matches demand geographically and technically, including identifying underused or overloaded sites and opportunities to optimize routing and platform placement.
What issues can lead to poor instrument utilization according to the notice?
The notice gives examples such as lack of reagents, maintenance gaps, insufficient training, power instability, or poor sample referral patterns.
Why is optimizing instrument utilization important?
The notice frames utilization optimization as a major cost and quality lever because it can improve turnaround time and test coverage without immediately requiring new capital purchases.
What is the national unique patient identifier intended to do?
It is intended to connect patient records across time and locations, ensure results are attributed to the correct person, reduce duplicate records, and support longitudinal tracking of patients over years of HIV care.
How does the notice connect the unique patient identifier to viral load monitoring?
The notice explicitly links it to tracking patients from one viral load test to the next so viral load suppression rates are accurate for all patients on ART.
What public health outcomes does the notice highlight?
The notice highlights improving measurement and progress toward viral load suppression among people on ART, expanding and strengthening early infant diagnosis (EID), and improving diagnosis and treatment for HIV/TB co-infection through strengthened integrated diagnostic services.
What does the notice say about early infant diagnosis coverage?
It indicates an aim to expand and strengthen early infant diagnosis, pushing coverage beyond a stated current level of 80%.
How is HIV/TB co-infection addressed in the opportunity?
The opportunity highlights HIV/TB co-infection explicitly, with an aim to ensure that HIV patients who are also infected with TB are properly diagnosed and treated, reflecting the importance of integrated HIV and TB diagnostic services.
When was the opportunity created, and what were the key dates listed?
The opportunity was created on March 3, 2021, with an original closing date of May 2, 2021.
How were applications required to be submitted?
Applications were required to be submitted electronically.
What was the submission deadline time zone and time?
Applications were due by 11:59 p.m. Eastern Time on the due date.
Who is eligible to apply?
Eligibility is listed broadly as "Others (see text field entitled Additional Information on Eligibility for clarification)," indicating the full announcement likely included additional eligibility conditions not shown in the excerpt.
What role does the Namibia Institute of Pathology (NIP) play in this opportunity?
The opportunity positions NIP as the operational backbone for national laboratory improvements, including serving as the platform for the national specimen transport system and supporting broader laboratory system strengthening.
What does the opportunity mean by improving "accessibility" and "quality assured" laboratory services?
Based on the notice, this refers to making diagnostic services more efficient and reachable through better transport and network design, while also improving reliability and timeliness of results through workflow improvements, effective instrument utilization, and stronger data systems such as a unique patient identifier.
How does this grant support outbreak response?
The notice indicates the strengthened laboratory system should help Namibia respond to outbreak needs by building more resilient transport, testing capacity, and data visibility across the diagnostic network.
Browse more opportunities from the same category: Health
Next opportunity: Support for Women-Owned SMEs in Less Privileged Communitiesin Sri Lanka
Previous opportunity: Alumni Engagement Innovation Fund (AEIF 2021)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH21 2157
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH21 2157) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening Urban Health Services and Models of Care in Kampala Capital City Authority (KCCA)- Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH21 2158 Funding Number: CDC RFA GH21 2158 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Technical Assistance (TA) to Support the Health Information Systems (HIS) of the South African Government to Improve Patient-level Data Systems at the National and Sub-National Departments of Health (DoH) under PEPFAR Apply for CDC RFA GH21 2123 Funding Number: CDC RFA GH21 2123 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH21 2160 Funding Number: CDC RFA GH21 2160 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP21 2101 Funding Number: CDC RFA IP21 2101 Agency: Department of Health and Human Services, Centers for Disease Control - NCIRD Category: Health Funding Amount: Case Dependent |
| Integrated HIV Care and Treatment Support Activity Apply for 72061321RFA00006 Funding Number: 72061321RFA00006 Agency: Agency for International Development, Zimbabwe USAID-Harare Category: Health Funding Amount: $70,000,000 |
| Advancing Health Literacy to Enhance Equitable Community Responses to COVID-19 Apply for MP CPI 21 006 Funding Number: MP CPI 21 006 Agency: Department of Health and Human Services, Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,000,000 |
| Strengthening Rocky Mountain spotted fever (RMSF) prevention and control in Arizona tribal lands Apply for CDC RFA CK21 2102 Funding Number: CDC RFA CK21 2102 Agency: Department of Health and Human Services, Centers for Disease Control - NCEZID Category: Health Funding Amount: $350,000 |
| Rigorously Evaluating Programs and Policies to Prevent Child Sexual Abuse (CSA) Apply for RFA CE 21 006 Funding Number: RFA CE 21 006 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $400,000 |
| Quality Improvement Solutions for Sustained Epidemic Control Project (QISSEC) Apply for HRSA 21 096 Funding Number: HRSA 21 096 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed) Apply for RFA OD 21 004 Funding Number: RFA OD 21 004 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) Apply for RFA OD 21 003 Funding Number: RFA OD 21 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $200,000 |
| Drug-Free Communities (DFC) Support Program Apply for CDC RFA CE21 2102 Funding Number: CDC RFA CE21 2102 Agency: Department of Health and Human Services, Centers for Disease Control - NCIPC Category: Health Funding Amount: $125,000 |
| Global Reach I Apply for HRSA 21 066 Funding Number: HRSA 21 066 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Emergency Triage, Treat, and Transport (ET3) Model Apply for CMS 2F2 21 001 Funding Number: CMS 2F2 21 001 Agency: Department of Health and Human Services, Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,175,000 |
| Improving the Health of People with Mobility Limitations and Intellectual/Developmental Disabilities through State-based Public Health Programs Apply for CDC RFA DD21 2103 Funding Number: CDC RFA DD21 2103 Agency: Department of Health and Human Services, Centers for Disease Control - NCBDDD Category: Health Funding Amount: $585,000 |
| National Viral Hepatitis Education, Awareness, and Capacity Building for Communities and Providers Apply for CDC RFA PS21 2105 Funding Number: CDC RFA PS21 2105 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Partnering with National Organizations to Support Community-Based Organizations to Increase Vaccination Coverage Across Different Racial and Ethnic Adult Populations Currently Experiencing Disparities Apply for CDC RFA IP21 2108 Funding Number: CDC RFA IP21 2108 Agency: Department of Health and Human Services, Centers for Disease Control - NCIRD Category: Health Funding Amount: Case Dependent |
| Radiation Health Protection Involving Ionizing and Non-Ionizing Radiation Apply for CDC RFA EH21 2103 Funding Number: CDC RFA EH21 2103 Agency: Department of Health and Human Services, Centers for Disease Control - NCEH Category: Health Funding Amount: $300,000 |
| Globally coordinated safety monitoring for COVID-19 vaccines Apply for CDC RFA CK21 2107 Funding Number: CDC RFA CK21 2107 Agency: Department of Health and Human Services, Centers for Disease Control - NCEZID Category: Health Funding Amount: $5,665,726 |
| Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed) Apply for RFA AI 21 035 Funding Number: RFA AI 21 035 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH21 2157", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.